Biomay Launches Fast-track Manufacturing for Personalized mRNA and DNA Cancer Vaccines
(October 21, 2026) Biomay highlights its dedicated manufacturing platform for neoantigen-based cancer vaccines. Designed for the demanding timelines of individualized cancer immunotherapies, it enables the production of personalized DNA cancer vaccines in as little as two weeks and mRNA-based vaccines in approximately three weeks from starting material to release.
> More info